about
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report.Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerId1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy.Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties.Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivoResponse of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibininEthics competences in the undergraduate medical education curriculum: the Spanish experience.A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.Targeting STAT3 with silibinin to improve cancer therapeutics.STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer.Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment.Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cellsSynthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.Paraneoplastic limbic encephalitis in a male with squamous cell carcinoma of the lung.Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report.Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity.Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer.[Teaching Bioethics to Students of Medicine with Problem-Based Learning (PBL)].EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.Silibinin is a direct inhibitor of STAT3.Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205.[Stem cells and cancer: elucidating the origin of the cancer stem cell]Somatic DICER1 mutations in adult-onset pulmonary blastoma.Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.
P50
Q33798713-CA182062-3D82-463A-932E-4132CF4C666FQ33878729-606556FC-B135-4254-B418-12A2CAC989ECQ34475138-B261B4DE-6371-414A-93B7-EF4EA0CF612EQ34483548-635FDB57-9862-4A9D-B6FE-C19441C124DBQ36350128-F468F9FD-A790-4976-8786-86701511F83EQ36597275-C040507A-12F4-4CE4-8C1B-AED8A5BEE61CQ36781090-759083CD-D291-40E4-BC0E-E50150D4457AQ37107787-0A2E15D0-4D49-4EB4-9AFD-DD7A9EF4E4CAQ37362587-DE5BAE11-1E11-4751-91DF-41DA3425E15BQ37479714-3AECA2D1-BCA3-493B-AC2C-2A0CB0CE24A3Q38375426-68B0B014-8F3F-48EB-9479-2D97ED2EB4B1Q38375429-1AE70CC6-43E1-4834-BAAA-231E5E575CDEQ38689192-1D993FC6-3F8F-4356-9781-92C5575E82DEQ38740295-A797994E-7A45-462B-B25E-1668F6DA8DC8Q38874166-91708425-CA6C-4434-BF58-BECD5F8FDD2BQ39101764-AA580CE0-06C2-4138-9D3F-9CC1B2830686Q39115260-120F94F5-43DC-44F1-83CA-08927EB39FCBQ40404944-0108E93F-D604-4C98-8A52-F6BC95C539EDQ40720253-4C2E0BE3-DB57-4D75-AC27-4B547E9C68A9Q41878464-20BCED5C-A6D3-403E-A9C7-C6E077F34FDBQ41978535-15441179-5489-4EBB-AE8B-F9F67C070A25Q42316814-827774A8-7CBE-4860-B0FA-C5E34A3E2E09Q42472069-BA7E5B09-C4CE-40F0-BFA7-3731BE280F86Q42508259-39DCFA88-68C6-4384-843E-50778D340A88Q42549526-4F836917-A21F-4D5A-B8AD-8B35C6E01296Q43241098-DBD0CD2F-166E-4B25-89C0-0FDC3D716EB1Q43264808-A9AE57DC-03DB-4DC3-87F8-5F9E16710DD0Q44110452-44227862-E090-4778-B645-A046F7085BFDQ47110103-278D1202-CFC1-4945-8540-A6C20C91DFC1Q50115431-CDD5E9F6-F2F7-445E-937F-4E8B10D2B48BQ50560916-019421DB-1366-4F79-A537-33260A8EDF59Q50969794-B7FC6A86-7BE5-47ED-BEE5-FAF04552C7D3Q51101727-0907A1A8-9F3F-437E-B001-6650D29C6170Q51705921-B1189093-4472-44DD-AB0B-A6F8183ECE12Q52585610-9D00CF8B-940A-4B89-9B42-635D1630CAF1Q53184000-9C96CF02-F7FD-47DE-B0B1-31C67205391EQ53328786-2C54A63D-4776-4EBB-ACFA-F78845DF5BE2Q54197750-E1B19769-7F4C-4C0B-891D-14F102237AFAQ54254026-CDA23D6A-CAAC-46D9-89C1-EEB50F70478BQ54522779-92728097-6B04-4C41-8C3B-A674F2FA14BD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joaquim Bosch-Barrera
@ast
Joaquim Bosch-Barrera
@en
Joaquim Bosch-Barrera
@es
Joaquim Bosch-Barrera
@sl
type
label
Joaquim Bosch-Barrera
@ast
Joaquim Bosch-Barrera
@en
Joaquim Bosch-Barrera
@es
Joaquim Bosch-Barrera
@sl
altLabel
Joaquim Bosch-Barrera
@en
prefLabel
Joaquim Bosch-Barrera
@ast
Joaquim Bosch-Barrera
@en
Joaquim Bosch-Barrera
@es
Joaquim Bosch-Barrera
@sl
P106
P1153
25637233500
P21
P31
P496
0000-0002-0893-7821